These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 25418186)

  • 1. Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial.
    Bissonnette R; Iversen L; Sofen H; Griffiths CE; Foley P; Romiti R; Bachinsky M; Rottinghaus ST; Tan H; Proulx J; Valdez H; Gupta P; Mallbris L; Wolk R
    Br J Dermatol; 2015; 172(5):1395-406. PubMed ID: 25418186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study.
    Papp KA; Menter A; Strober B; Langley RG; Buonanno M; Wolk R; Gupta P; Krishnaswami S; Tan H; Harness JA
    Br J Dermatol; 2012 Sep; 167(3):668-77. PubMed ID: 22924949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tofacitinib (CP-690,550), an oral Janus kinase inhibitor, improves patient-reported outcomes in a phase 2b, randomized, double-blind, placebo-controlled study in patients with moderate-to-severe psoriasis.
    Mamolo C; Harness J; Tan H; Menter A
    J Eur Acad Dermatol Venereol; 2014 Feb; 28(2):192-203. PubMed ID: 23294276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis.
    Ports WC; Khan S; Lan S; Lamba M; Bolduc C; Bissonnette R; Papp K
    Br J Dermatol; 2013 Jul; 169(1):137-45. PubMed ID: 23387374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment.
    Strober B; Buonanno M; Clark JD; Kawabata T; Tan H; Wolk R; Valdez H; Langley RG; Harness J; Menter A; Papp K
    Br J Dermatol; 2013 Nov; 169(5):992-9. PubMed ID: 23855761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study.
    McInnes IB; Kim HY; Lee SH; Mandel D; Song YW; Connell CA; Luo Z; Brosnan MJ; Zuckerman A; Zwillich SH; Bradley JD
    Ann Rheum Dis; 2014 Jan; 73(1):124-31. PubMed ID: 23482473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extension.
    Reich K; Ortonne JP; Gottlieb AB; Terpstra IJ; Coteur G; Tasset C; Mease P
    Br J Dermatol; 2012 Jul; 167(1):180-90. PubMed ID: 22413944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.
    Burmester GR; Blanco R; Charles-Schoeman C; Wollenhaupt J; Zerbini C; Benda B; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Soma K; Bradley J; Mebus C;
    Lancet; 2013 Feb; 381(9865):451-60. PubMed ID: 23294500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis.
    Sandborn WJ; Ghosh S; Panes J; Vranic I; Su C; Rousell S; Niezychowski W;
    N Engl J Med; 2012 Aug; 367(7):616-24. PubMed ID: 22894574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years.
    Kimball AB; Gordon KB; Fakharzadeh S; Yeilding N; Szapary PO; Schenkel B; Guzzo C; Li S; Papp KA
    Br J Dermatol; 2012 Apr; 166(4):861-72. PubMed ID: 22356258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adalimumab for moderate to severe chronic plaque psoriasis: efficacy and safety of retreatment and disease recurrence following withdrawal from therapy.
    Papp K; Crowley J; Ortonne JP; Leu J; Okun M; Gupta SR; Gu Y; Langley RG
    Br J Dermatol; 2011 Feb; 164(2):434-41. PubMed ID: 21083543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of infliximab vs. methotrexate in patients with moderate-to-severe plaque psoriasis: results of an open-label, active-controlled, randomized trial (RESTORE1).
    Barker J; Hoffmann M; Wozel G; Ortonne JP; Zheng H; van Hoogstraten H; Reich K
    Br J Dermatol; 2011 Nov; 165(5):1109-17. PubMed ID: 21910713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: a controlled comparison with calcipotriene (calcipotriol) cream.
    Alora-Palli MB; Perkins AC; Van Cott A; Kimball AB
    Am J Clin Dermatol; 2010; 11(4):275-83. PubMed ID: 20513160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial.
    Kremer J; Li ZG; Hall S; Fleischmann R; Genovese M; Martin-Mola E; Isaacs JD; Gruben D; Wallenstein G; Krishnaswami S; Zwillich SH; Koncz T; Riese R; Bradley J
    Ann Intern Med; 2013 Aug; 159(4):253-61. PubMed ID: 24026258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Once weekly administration of etanercept 50 mg is efficacious and well tolerated in patients with moderate-to-severe plaque psoriasis: a randomized controlled trial with open-label extension.
    van de Kerkhof PC; Segaert S; Lahfa M; Luger TA; Karolyi Z; Kaszuba A; Leigheb G; Camacho FM; Forsea D; Zang C; Boussuge MP; Paolozzi L; Wajdula J
    Br J Dermatol; 2008 Nov; 159(5):1177-85. PubMed ID: 18673365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study.
    Papp KA; Langley RG; Sigurgeirsson B; Abe M; Baker DR; Konno P; Haemmerle S; Thurston HJ; Papavassilis C; Richards HB
    Br J Dermatol; 2013 Feb; 168(2):412-21. PubMed ID: 23106107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone.
    Kremer JM; Cohen S; Wilkinson BE; Connell CA; French JL; Gomez-Reino J; Gruben D; Kanik KS; Krishnaswami S; Pascual-Ramos V; Wallenstein G; Zwillich SH
    Arthritis Rheum; 2012 Apr; 64(4):970-81. PubMed ID: 22006202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
    van Vollenhoven RF; Fleischmann R; Cohen S; Lee EB; García Meijide JA; Wagner S; Forejtova S; Zwillich SH; Gruben D; Koncz T; Wallenstein GV; Krishnaswami S; Bradley JD; Wilkinson B;
    N Engl J Med; 2012 Aug; 367(6):508-19. PubMed ID: 22873531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between pruritus and the clinical signs of psoriasis in patients receiving tofacitinib.
    Bushmakin AG; Mamolo C; Cappelleri JC; Stewart M
    J Dermatolog Treat; 2015 Feb; 26(1):19-22. PubMed ID: 24289224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.